Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Nuvalent, Inc.NASDAQ: NUVL
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns negative
Q1 FY2026 investing cash flow was -$19.41M, compared with $25.42M a year earlier. Trailing-twelve-month investing cash flow was -$168.91M. Over 3 fiscal years it compounded at +126.6% a year.
Context
- Investing cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near -$19.41M or moves back toward the trailing-twelve-month quarterly average of -$42.23M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (124.08M) USD
- Year-over-year change
- +78.4%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (124.08M) | +78.4% |
| FY2024 | 2024-12-31 | (573.51M) | -299.6% |
| FY2023 | 2023-12-31 | (143.53M) | -1245.8% |
| FY2022 | 2022-12-31 | (10.67M) | +95.2% |
| FY2021 | 2021-12-31 | (220.03M) | — |
Investing Cash Flow vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.5% is the 5th highest of 9, against a peer median of -60.0%.
- Over three fiscal years its annual growth of +126.6% compares with a peer median of +26.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $977.96M USD | -26.5% | +50.1% | 20.7% | |
| LTM Sep 2026 | $670.48M USD | +418.6% | +91.0% | 148.7% | |
| LTM Jun 2026 | $503.68M USD | -324.2% | — | 709.8% | |
| LTM Sep 2026 | $443.29M USD | -1303.8% | -50.3% | 1761.0% | |
| LTM Mar 2026 | $168.91M USD | -50.5% | +126.6% | — | |
| LTM Sep 2026 | $85.31M USD | +158.3% | — | 30.4% | |
| LTM Jun 2026 | $82.81M USD | -93.5% | +80.3% | — | |
| FY2025 | €13.18M EUR | -183.6% | +3.1% | — | |
| LTM Jun 2026 | $700K USD | +48.6% | -79.2% | 0.1% | |
| Peer median (excluding NUVL) | — | -60.0% | +26.6% | 89.6% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Depreciation & Amortization | 215K | (373K) | 0 | 0 | 0 |
| Deferred Income Tax | (215K) | (5.74M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.55M | 10.33M | 25.56M | 60.58M | 86.5M |
| Change in Working Capital | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.64M | 4.21M | 2.17M | (4.05M) | 24.6M |
| Other Working Capital | 300K | 2.72M | 8.86M | 15.89M | (5.39M) |
| Other Non-Cash Items | 846K | 5.74M | (10.11M) | 3.27M | 44.46M |
| Operating Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.04M) | (212.92M) | (459.49M) | (1.02B) | (1.06B) |
| Sales of Investments | 1.02M | 202.25M | 315.96M | 451.45M | 933.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (220.03M) | (10.67M) | (143.53M) | (573.51M) | (124.08M) |
| Debt Repayment | 284K | 0 | 0 | 0 | 0 |
| Common Stock Issued | 177.27M | 248.63M | 324.3M | 569.99M | 515.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.98M) | 286K | 12.55M | (1.11M) | 0 |
| Financing Cash Flow | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 58.19M | 173.28M | 93.58M | (189.7M) | 116.05M |
| Free Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.